The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Pankaj M. Madhani - One of the best experts on this subject based on the ideXlab platform.
-
Clinical and Contract Research Potential: A Resource Based View (RBV) Approach
2010Co-Authors: Pankaj M. MadhaniAbstract:The purpose of this paper is to discuss the resources that have contributed to the competitive position of the Indian clinical and Contract Research organizations (CROs). In accordance to resource based view (RBV) approach, the main source of firm's market performance lies on the specific nature of their resources and accumulated competences. A combination of resources including supportive government policies, size and composition of population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian CROs. RBV helps explain the contribution of various resources and capabilities to the Indian CROs.
-
Clinical and Contract Research: Potential
SCMS Journal of Indian Management, 2010Co-Authors: Pankaj M. MadhaniAbstract:The purpose of this paper is to discuss the resources that have contributed to the competitive position of the Indian clinical and Contract Research organizations (CROs). In accordance to resource based view (RBV) approach, the main source of firm's market performance lies on the specific nature of their resources and accumulated competences. A combination of resources including supportive government policies, size and composition of population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian CROs. RBV helps explain the contribution of various resources and capabilities to the Indian CROs.
-
A Resource Based View (RBV) of Indian Clinical and Contract Research Sector
2008Co-Authors: Pankaj M. MadhaniAbstract:Paper discusses the resources that have contributed to the competitive position of the Indian clinical and Contract Research sector and analyze the case using the RBV (Resource Based View) of strategy. RBV helps explain the contribution of various resources to the Indian clinical and Contract Research sector. India is emerging as a natural choice and ultimate destination for Contract clinical Research services. India’s competitive advantages in clinical trials and Contract Research are based on favorable regulatory climate, a huge population with a diversity of diseases, sound infrastructure facilities, lower infrastructure costs, English language proficiency of doctors, staff of hospital, clinical analysts and investigators, large pool of treatment naive patients, high speed of subject recruitment, good patient compliance and retention rate and low cost of clinical studies. Clinical and Contract Research is a rapidly growing industry in India. Many pharmaceutical organizations and Contract Research firms have started to extract the vast potential that India has, and are conducting clinical trials and Contract Research activities in India on a big scale. A combination of resources including supportive government policies, size and composition of population, skilled workforce, sound medical infrastructure, established pharma industry, and global linkages etc. help create a sustainable advantage for the Indian clinical and Contract Research sector. Paper discusses opportunities for Indian clinical and Contract Research industry, its growth drivers in terms of resources, and emerging challenges.
Anupama Bhadauria - One of the best experts on this subject based on the ideXlab platform.
-
Emerging trends in Contract Research industry in India
Contemporary clinical trials, 2010Co-Authors: Sushma Drabu, Alka Gupta, Anupama BhadauriaAbstract:A Contract Research Organization (CRO) is a service organization that provides support to the pharmaceutical industry and offers a wide range of "outsourced" pharmaceutical Research services to aid in R&D process and is thus an essential tool for undertaking clinical trials in the present scenario when high stakes are involved in the drug discovery process. This industry also offers a safe option of investment as the industry is largely recession-proof, with a significant upscale growth. Presently India occupies a very small pie of the global market share in the Clinical Trials Industry but it is estimated to conduct nearly 5% of global clinical trials by 2012. The global CRO industry valued $18 bn in 2008 and the market is expected to grow at an annual rate of 14% between 2009 and 13. Top multinational pharmaceuticals companies are venturing into the Indian business, in collaboration with the Indian Drug Companies. According to a recent study by Mckinsey & Company, the Indian Clinical Research Industry can attract $1.5 bn of revenue from US and EU by 2010. Such an increase in outsourcing from the western countries has led the global pharma companies and Indian entrepreneurs to set up Contract Research Organizations (CROs) in India. To bring this into realization and fulfil the market demand, while simultaneously aiding in improving the country's economical standards and market position, joint and well-coordinated efforts on part of the government, industry, and working professionals are needed in terms of regulatory affairs, audits, transparency in work affairs, garnering patient confidence, and pharmacovigilance.
Qiu Jiaxue - One of the best experts on this subject based on the ideXlab platform.
-
The Present Status and Future of Contract Research Organization
Progress in Pharmaceutical Sciences, 2007Co-Authors: Qiu JiaxueAbstract:As a new profession,Contract Research Organization(CRO) industry was developed pretty quickly in recent years globally.More than 500 CRO companies play an important role in operation control,cost control and risk control of drug development all over the world.CRO industry is still on its early stage in China,which means opportunities and challenges exist simultaneously in this profession.CRO will undoubtedly promote the drug Research and development to an unprecedented status.CRO industry should be supported strongly,encouraged to set up various types and guided by related policies and regulations.CRO companies should keep collecting and summarizing experiences to improve,and building brands in preciseness,standard and effectiveness to gain more market share.CRO companies should also set up their own databases to manage,analyze data,and explore in publicizing clinic experiment data by information systems.
Sushma Drabu - One of the best experts on this subject based on the ideXlab platform.
-
Emerging trends in Contract Research industry in India
Contemporary clinical trials, 2010Co-Authors: Sushma Drabu, Alka Gupta, Anupama BhadauriaAbstract:A Contract Research Organization (CRO) is a service organization that provides support to the pharmaceutical industry and offers a wide range of "outsourced" pharmaceutical Research services to aid in R&D process and is thus an essential tool for undertaking clinical trials in the present scenario when high stakes are involved in the drug discovery process. This industry also offers a safe option of investment as the industry is largely recession-proof, with a significant upscale growth. Presently India occupies a very small pie of the global market share in the Clinical Trials Industry but it is estimated to conduct nearly 5% of global clinical trials by 2012. The global CRO industry valued $18 bn in 2008 and the market is expected to grow at an annual rate of 14% between 2009 and 13. Top multinational pharmaceuticals companies are venturing into the Indian business, in collaboration with the Indian Drug Companies. According to a recent study by Mckinsey & Company, the Indian Clinical Research Industry can attract $1.5 bn of revenue from US and EU by 2010. Such an increase in outsourcing from the western countries has led the global pharma companies and Indian entrepreneurs to set up Contract Research Organizations (CROs) in India. To bring this into realization and fulfil the market demand, while simultaneously aiding in improving the country's economical standards and market position, joint and well-coordinated efforts on part of the government, industry, and working professionals are needed in terms of regulatory affairs, audits, transparency in work affairs, garnering patient confidence, and pharmacovigilance.
Alka Gupta - One of the best experts on this subject based on the ideXlab platform.
-
Emerging trends in Contract Research industry in India
Contemporary clinical trials, 2010Co-Authors: Sushma Drabu, Alka Gupta, Anupama BhadauriaAbstract:A Contract Research Organization (CRO) is a service organization that provides support to the pharmaceutical industry and offers a wide range of "outsourced" pharmaceutical Research services to aid in R&D process and is thus an essential tool for undertaking clinical trials in the present scenario when high stakes are involved in the drug discovery process. This industry also offers a safe option of investment as the industry is largely recession-proof, with a significant upscale growth. Presently India occupies a very small pie of the global market share in the Clinical Trials Industry but it is estimated to conduct nearly 5% of global clinical trials by 2012. The global CRO industry valued $18 bn in 2008 and the market is expected to grow at an annual rate of 14% between 2009 and 13. Top multinational pharmaceuticals companies are venturing into the Indian business, in collaboration with the Indian Drug Companies. According to a recent study by Mckinsey & Company, the Indian Clinical Research Industry can attract $1.5 bn of revenue from US and EU by 2010. Such an increase in outsourcing from the western countries has led the global pharma companies and Indian entrepreneurs to set up Contract Research Organizations (CROs) in India. To bring this into realization and fulfil the market demand, while simultaneously aiding in improving the country's economical standards and market position, joint and well-coordinated efforts on part of the government, industry, and working professionals are needed in terms of regulatory affairs, audits, transparency in work affairs, garnering patient confidence, and pharmacovigilance.